Parmax Pharma Ltd - 540359 - Clarification sought from Parmax Pharma Ltd
The Exchange has sought clarification from Parmax Pharma Ltd on June 23, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. Parmax Pharma Ltd - 540359 - Outcome Of Board Meeting And Results For Quarter And Financial Year Ended 31St March, 2022.
Outcome of Board Meeting and Results for Quarter and Financial year ended 31st March, 2022. Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Outcome Of Board Meeting And Results For Quarter And Financial Year Ended 31St March, 2022.
Outcome of Board Meeting and Results for Quarter and Financial year ended 31st March, 2022. Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Parmax Pharma Ltd - 540359 - Disclosure In Pursuance Of SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 Dated 26TH November, 2018.
We would like to inform you that our company is not falling under the category of "Large Corporate (LC)" as per the framework provided in the aforesaid Circular. Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March, 2022. Parmax Pharma Ltd - 540359 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31St March, 2022.
Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2022. Parmax Pharma Ltd - 540359 - Compliance Certificate Pursuant To Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2022
Compliance Certificate pursuant to Regulation 7(3) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 for the financial year ended on 31st March, 2022 Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer